Sign In
Buy TARS
$58.76
+1.35 (+2.35%)
At Close: Jun 03, 2026
Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $279,658.00 in Stock
05:06am, Sunday, 22'nd Mar 2026
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS - Get Free Report) insider Dianne Whitfield sold 4,174 shares of the business's stock in a transaction on Thursday, March 19th. The stock was sold at an aver
Tarsus Pharmaceuticals (NASDAQ:TARS) General Counsel Sells $283,428.75 in Stock
05:06am, Sunday, 22'nd Mar 2026
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS - Get Free Report) General Counsel Bryan Wahl sold 4,125 shares of the firm's stock in a transaction on Wednesday, March 18th. The stock was sold at an avera
Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $279,718.41 in Stock
05:06am, Sunday, 22'nd Mar 2026
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS - Get Free Report) insider Dianne Whitfield sold 4,071 shares of the company's stock in a transaction dated Wednesday, March 18th. The stock was sold at an a
Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) General Counsel Sells $283,511.28 in Stock
05:06am, Sunday, 22'nd Mar 2026
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS - Get Free Report) General Counsel Bryan Wahl sold 4,084 shares of the firm's stock in a transaction dated Tuesday, March 17th. The shares were sold at an av
Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $279,693.18 in Stock
05:06am, Sunday, 22'nd Mar 2026
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS - Get Free Report) insider Dianne Whitfield sold 4,029 shares of the company's stock in a transaction that occurred on Tuesday, March 17th. The stock was sol
Tarsus Pharmaceuticals (NASDAQ:TARS) General Counsel Sells $283,477.00 in Stock
05:06am, Sunday, 22'nd Mar 2026
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS - Get Free Report) General Counsel Bryan Wahl sold 4,231 shares of the company's stock in a transaction on Thursday, March 19th. The shares were sold at an a
Ally Bridge Group NY LLC Decreases Stake in Tarsus Pharmaceuticals, Inc. $TARS
03:31am, Sunday, 15'th Mar 2026
Ally Bridge Group NY LLC cut its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) by 41.6% during the third quarter, according to the company in its most recent filing with the Securitie
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
02:42pm, Wednesday, 11'th Mar 2026
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Citigroup Inc. Increases Position in Tarsus Pharmaceuticals, Inc. $TARS
04:36am, Sunday, 08'th Mar 2026
Citigroup Inc. raised its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) by 78.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional
Tarsus to Participate in Upcoming Investor Conferences
04:30pm, Thursday, 26'th Feb 2026
IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
Tarsus Pharmaceuticals: Q4 Results Highlight Xdemvy Blockbuster Potential
01:47pm, Tuesday, 24'th Feb 2026
Tarsus Pharmaceuticals remains a Strong Buy, driven by Xdemvy's robust growth and management's $2B+ peak sales target. FY 2025 revenue surged 150% to $451M, with 2026 guidance at $670–$700M and 93%
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call Transcript
06:15am, Tuesday, 24'th Feb 2026
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates
08:26pm, Monday, 23'rd Feb 2026
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.6 per share a year ago.
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
08:30am, Wednesday, 18'th Feb 2026
IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutic
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026
04:30pm, Tuesday, 17'th Feb 2026
IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23, 2
